Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, et al. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. Clin Genitourin Cancer. 2019;17:231–7.e2.

Article  PubMed  Google Scholar 

Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology. 2012;60:59–74.

Article  PubMed  Google Scholar 

Samaratunga H, Duffy D, Yaxley J, Delahunt B. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol. 2010;41:281–5.

Article  PubMed  Google Scholar 

Kim A, Kwon T, You D, Jeong IG, Go H, Cho YM, et al. Clinicopathological features of prostate ductal carcinoma: matching analysis and comparison with prostate acinar carcinoma. J Korean Med Sci. 2015;30:385–9.

Article  PubMed  PubMed Central  Google Scholar 

Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, et al. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2021;79:298–306.

Article  CAS  PubMed  Google Scholar 

Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone N, Thompson TC, et al. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol. 2021;18:337–58.

Article  PubMed  Google Scholar 

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70:106–19.

Article  PubMed  Google Scholar 

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016;40:244–52.

Article  PubMed  Google Scholar 

van Leenders G, van der Kwast TH, Grignon DJ, Evans AJ, Kristiansen G, Kweldam CF, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87–e99.

Article  PubMed  PubMed Central  Google Scholar 

Epstein JI, Amin MB, Fine SW, Algaba F, Aron M, Baydar DE, et al. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer. Arch Pathol Lab Med 2021;145:461–93.

Article  PubMed  Google Scholar 

Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, et al. Knowing what’s growing: Why ductal and intraductal prostate cancer matter. Sci Transl Med. 2020;12:eaaz0152.

Jang WS, Shin SJ, Yoon CY, Kim MS, Kang DH, Kang YJ, et al. Prognostic Significance of the Proportion of Ductal Component in Ductal Adenocarcinoma of the Prostate. J Urol. 2017;197:1048–53.

Article  PubMed  Google Scholar 

Harkin T, Elhage O, Chandra A, Khan N, Kiberu Y, Frydenberg M, et al. High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma. BJU Int. 2019;124:907–9.

Article  PubMed  Google Scholar 

Jeong SU, Kekatpure AK, Park JM, Han M, Hwang HS, Jeong HJ, et al. Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors. J Pathol Transl Med. 2017;51:471–81.

Article  PubMed  PubMed Central  Google Scholar 

Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer. 1991;67:2118–24.

Article  CAS  PubMed  Google Scholar 

Seipel AH, Wiklund F, Wiklund NP, Egevad L. Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch: Int J Pathol 2013;462:429–36.

Article  Google Scholar 

Tu SM, Lopez A, Leibovici D, Bilen MA, Evliyaoglu F, Aparicio A, et al. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009;115:2872–80.

Article  PubMed  Google Scholar 

Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol. 2017;72:492–5.

Article  PubMed  Google Scholar 

Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol. 2006;19:1528–35.

Article  PubMed  Google Scholar 

Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. Eur Urol. 2020;77:403–17.

Article  PubMed  Google Scholar 

Isik EG, Has-Simsek D, Sanli O, Sanli Y, Kuyumcu S. Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. Clin Nucl Med. 2022;47:e54–e5.

Article  PubMed  Google Scholar 

Khreish F, Rosar F, Kratochwil C, Giesel FL, Haberkorn U, Ezziddin S. Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease. Eur J Nucl Med Mol imaging. 2020;47:2040–1.

Article  PubMed  Google Scholar 

Parida GK, Tripathy S, Datta Gupta S, Singhal A, Kumar R, Bal C, et al. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. Clin Nucl Med. 2018;43:248–9.

Article  PubMed  Google Scholar 

Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A Prospective Trial of (68)Ga-PSMA and (18)F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration. Clin Cancer Res. 2020;26:4551–8.

Article  CAS  PubMed  Google Scholar 

Chen R, Wang Y, Shi Y, Zhu Y, Xu L, Huang G, et al. Diagnostic value of (18)F-FDG PET/CT in patients with biochemical recurrent prostate cancer and negative (68)Ga-PSMA PET/CT. Eur J Nucl Med Mol Imaging. 2021;48:2970–7.

Article  PubMed  Google Scholar 

Qiu S, Dong A, Zhu Y, Zuo C. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate. Clin Nucl Med. 2022;47:836–8.

Article  PubMed  Google Scholar 

Meziou S, Ringuette Goulet C, Hovington H, Lefebvre V, Lavallée É, Bergeron M, et al. GLUT1 expression in high-risk prostate cancer: correlation with (18)F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis. 2020;23:441–8.

Article  CAS  PubMed  Google Scholar 

Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna SN, Mukherjee R, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology. 2006;48:787–94.

Article  CAS  PubMed  Google Scholar 

Munkley J, McClurg UL, Livermore KE, Ehrmann I, Knight B, McCullagh P, et al. The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Sci Rep. 2017;7:5249.

Article  PubMed  PubMed Central  Google Scholar 

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical cancer research: an official journal of the American Association for. Cancer Res. 1997;3:81–5.

CAS  Google Scholar 

Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, et al. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology. 2013;22:2354–63.

CAS  Google Scholar 

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82:2256–61.

Article  CAS  PubMed  Google Scholar 

Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. Eur Urol. 2019;76:469–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barron CC, Bilan PJ, Tsakiridis T, Tsiani E. Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism. 2016;65:124–39.

Article  CAS  PubMed  Google Scholar 

Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? Int J Cancer. 2018;142:2414–24.

Article  CAS  PubMed  Google Scholar 

Jadvar H. PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer. J Nucl Med. 2016;57:25s–9s.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo GI, Soeterik T, Puche-Sanz I, Broggi G, Lo Giudice A, De Nunzio C, et al. Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:646–54.